BiotechTube

Azacitidine + Azacitidine plus Deferasirox

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

High Risk MDS

Conditions

High Risk MDS

Trial Timeline

Sep 11, 2014 → Jun 26, 2015

NCT ID
NCT02159040

About Azacitidine + Azacitidine plus Deferasirox

Azacitidine + Azacitidine plus Deferasirox is a phase 2 stage product being developed by Novartis for High Risk MDS. The current trial status is terminated. This product is registered under clinical trial identifier NCT02159040. Target conditions include High Risk MDS.

What happened to similar drugs?

6 of 20 similar drugs in High Risk MDS were approved

Approved (6) Terminated (7) Active (9)
✅Bunazosin + Doxazosin + ValsartinEisaiApproved
✅AliskirenNovartisApproved
✅Aliskiren and HCTZNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
✅Escitalopram + Placebo oral tabletLundbeckApproved
✅losartan potassium + Comparator: PlaceboOrganonApproved
❌Edoxaban + ASADaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02159040Phase 2Terminated

Competing Products

20 competing products in High Risk MDS

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Sepantronium BromideCothera BiosciencePhase 2
29
Edoxaban + ASADaiichi SankyoPhase 3
32
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
36
Bunazosin + Doxazosin + ValsartinEisaiApproved
43
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3
47
Camrelizumab、Rivoceranib + CamrelizumabJiangsu Hengrui MedicinePhase 2
35
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Mirvetuximab SoravtansineAbbViePhase 2
42
Zibotentan/Dapagliflozin + DapagliflozinAstraZenecaPhase 2
42
AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tabletAstraZenecaPhase 1
29
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
40
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
40